We believe that in addition to the physiologic PSMA expression, COVID-19 vaccination–induced cellular and humoral immune responses in lymph nodes could augment the preexisting PSMA expression and thus enhance the avidity of PSMA ligands in nonmetastatic lymph nodes in patients with prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.